ArticleNPJ precision oncology2026
HRD in endometrial cancer: LST loss drives distinct genomic profile and platinum response.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
While homologous recombination deficiency (HRD) presents therapeutic opportunities in endometrial cancer (EC), its molecular determinants and clinical implications remain poorly characterized. Through genomic analysis of 688 cancer-related genes combined with genomic scar assessment, we investigated HRD molecular features and clinical relevance of HRD across three cohorts: an EC cohort from Sun Yat-sen University Cancer Center (SYSUCC, n = 114), the Cancer Genome Atlas EC cohort (n = 500), and a high-grade serous ovarian cancer (HGSOC) cohort (n = 118). HRD was identified in 23.7% of SYSUCC EC cases, and HRD tumors paradoxically had fewer short-nucleotide variations in HRR genes than proficient (HRP) tumors (18.52% vs. 48.28%, P = 0.007). Mechanistic analysis revealed large-scale transition (LST) losses as the potential predominant HRD driver in EC, occurring significantly more frequently in HRD versus HRP tumors (74.1% vs 5.7%; P < 0.001). Comparative genomics demonstrated enrichment of HRR gene LST losses was EC-specific, contrasting with HGSOC where LST distribution was HRD-independent. Clinically, elevated HRD scores predicted reduced progression-free survival (HR 1.74, 95% CI 1.03-2.94; P = 0.04) yet enhanced platinum sensitivity (HR 0.41, 95% CI 0.18-0.94; P = 0.034). Our findings indicate that the HRD phenotype in EC, driven primarily by LST losses rather than short-nucleotide variations, serves as both a prognostic and predictive biomarker.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.